GlassScriptPhysician profile
Christopher Darienzo
NPI 1376608927
$3,304.89
in general payments reported to CMS, 2019-2025
26 companies · $536 in 2025
The $536 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $458 · 2022: $748 · 2023: $658 · 2024: $905 · 2025: $536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,099.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,098.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $433.72 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $383.41 | 2021-2024 | |
| Abbott Laboratories | $369.92 | 2021-2024 | Cardiomems |
| Amgen INC. | $347.81 | 2022-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $293.39 | 2021-2024 | Xarelto, Pinnacle |
| Medtronic, INC. | $219.13 | 2024 | Cg Future |
| Philips North America LLC | $215.18 | 2023-2025 | Accessories, (5091) Amb Mon & Diag Und |
| Amarin Pharma, INC. | $126.86 | 2021-2022 | |
| Novo Nordisk INC | $124.64 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Daiichi Sankyo INC. | $93.56 | 2023-2024 | Injectafer |
| Kestra Medical Technology Services, INC. | $84.41 | 2023 | Assure Wcd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.87 | 2022-2025 | Jardiance |
| Esperion Therapeutics, INC. | $68.38 | 2022-2024 | Nexletol |
| Irhythm Technologies, INC. | $61.11 | 2024 | Zio Monitor, Zio Xt Patch |
| E.R. Squibb & Sons, L.L.C. | $61.08 | 2022-2025 | Camzyos, Eliquis |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $58.05 | 2025 | Amvuttra |
| Tactile Systems Technology INC | $57.42 | 2023-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| Astrazeneca Pharmaceuticals LP | $42.47 | 2022-2025 | Lokelma |
| Lexicon Pharmaceuticals, INC. | $34.64 | 2023-2024 | Inpefa |
| Merck Sharp & Dohme LLC | $32.38 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $28.47 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $20.79 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $19.48 | 2024 | Arcalyst |
| Bridgebio Pharma, INC. | $18.46 | 2025 | Attruby |
| Kiniksa Pharmaceuticals, LTD. | $15.20 | 2023 | Arcalyst |
| Heartflow, INC. | $15.06 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Darienzo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.